Orthofix Medical (NASDAQ:OFIX) CFO Julie Andrews Sells 4,873 Shares of Stock

Orthofix Medical Inc. (NASDAQ:OFIX) CFO Julie Andrews sold 4,873 shares of the business’s stock in a transaction on Friday, January 16th. The shares were sold at an average price of $14.38, for a total value of $70,073.74. Following the transaction, the chief financial officer owned 58,039 shares of the company’s stock, valued at approximately $834,600.82. The trade was a 7.75% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Orthofix Medical Trading Up 1.5%

OFIX stock traded up $0.21 during midday trading on Wednesday, reaching $13.85. The company’s stock had a trading volume of 162,693 shares, compared to its average volume of 213,984. Orthofix Medical Inc. has a 1 year low of $10.24 and a 1 year high of $20.48. The firm has a market capitalization of $548.46 million, a price-to-earnings ratio of -4.57 and a beta of 0.79. The stock has a fifty day simple moving average of $15.30 and a two-hundred day simple moving average of $14.36. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.38 and a current ratio of 2.47.

Institutional Investors Weigh In On Orthofix Medical

Several institutional investors and hedge funds have recently made changes to their positions in OFIX. Paradigm Capital Management Inc. NY increased its holdings in Orthofix Medical by 34.6% in the 2nd quarter. Paradigm Capital Management Inc. NY now owns 3,340,600 shares of the medical device company’s stock worth $37,248,000 after buying an additional 858,900 shares during the period. Millennium Management LLC boosted its holdings in shares of Orthofix Medical by 86.6% in the 3rd quarter. Millennium Management LLC now owns 1,475,718 shares of the medical device company’s stock valued at $21,605,000 after acquiring an additional 684,850 shares during the last quarter. Bank of America Corp DE increased its stake in shares of Orthofix Medical by 659.5% in the second quarter. Bank of America Corp DE now owns 687,410 shares of the medical device company’s stock worth $7,665,000 after acquiring an additional 596,907 shares during the period. Engine Capital Management LP raised its holdings in shares of Orthofix Medical by 13.6% during the second quarter. Engine Capital Management LP now owns 4,251,671 shares of the medical device company’s stock worth $47,406,000 after purchasing an additional 510,281 shares during the last quarter. Finally, AYAL Capital Advisors Ltd lifted its position in Orthofix Medical by 74.7% during the second quarter. AYAL Capital Advisors Ltd now owns 943,203 shares of the medical device company’s stock valued at $10,517,000 after purchasing an additional 403,433 shares during the period. 89.76% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

OFIX has been the topic of several recent research reports. Barrington Research increased their target price on Orthofix Medical from $17.00 to $18.00 and gave the company an “outperform” rating in a research report on Wednesday, November 5th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Orthofix Medical in a report on Wednesday, October 8th. Finally, Stifel Nicolaus began coverage on shares of Orthofix Medical in a report on Tuesday, October 28th. They issued a “buy” rating and a $22.00 price target on the stock. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $21.50.

About Orthofix Medical

Orthofix Medical Inc (NASDAQ: OFIX) is a global medical device company focused on the design and development of innovative orthopedic and spinal solutions. The company’s core business is divided into two segments: spine and orthopedics. In the spine segment, Orthofix offers a range of titanium implants, biologics and portable bone growth stimulation devices designed to support spinal fusion, deformity correction and minimally invasive procedures. Its orthopedic segment encompasses products for fracture fixation, external fixation systems, trauma care and sports medicine, providing surgeons with implantable devices and instruments for complex bone reconstruction and healing.

Orthofix’s product portfolio includes strut systems, bone growth stimulators, interbody fusion devices and fixation hardware that address various indications such as degenerative disc disease, spinal deformities, non-unions and long-bone fractures.